AR and neoplasm: A greater understanding of the LAR group has led to the ongoing evolution of therapeutic combinations, including those of AR inhibitors with PI3K inhibitors given the frequent co-amplification of PIK3CA in AR-positive tumours, which is estimated to be as high as 40%.